MorphoSys AG Company Profile (ETR:MOR)

About MorphoSys AG (ETR:MOR)

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The company’s product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. The company was founded in 1992 and is headquartered in Planegg, Germany.


Frequently Asked Questions for MorphoSys AG (ETR:MOR)

What is MorphoSys AG's stock symbol?

MorphoSys AG trades on the ETR under the ticker symbol "MOR."

Where is MorphoSys AG's stock going? Where will MorphoSys AG's stock price be in 2017?

7 brokers have issued twelve-month price targets for MorphoSys AG's stock. Their forecasts range from €55.00 to €90.00. On average, they expect MorphoSys AG's share price to reach €69.57 in the next twelve months. View Analyst Ratings for MorphoSys AG.

Who are some of MorphoSys AG's key competitors?

Some companies that are related to MorphoSys AG include Aareal Bank AG (ARL), Adler Real Estate AG (ADL), ADO Properties SA (ADJ), ADVA Optical Networking SE (ADV), Aixtron Se (AIXA), Aurubis AG (NDA), Basf Se (BAS), Bayerische Motoren Werke AG (BMW), BayWa AG (BYW6), Bechtle AG (BC8), Beiersdorf AG (BEI), Bertrandt AG (BDT), bet-at-home.com AG (ACX), Bilfinger SE (GBF), Biotest AG (BIO), Cancom SE (COK), Capital Stage AG (CAP) and Carl Zeiss Meditec AG (AFX).

Who are MorphoSys AG's key executives?

MorphoSys AG's management team includes the folowing people:

• Gerald Moeller, Chairman of the Supervisory Board
• Simon E. Moroney Ph.D., Member of the Management Board, Chief Executive Officer
• Jens Holstein, Chief Financial Officer, Member of the Management Board
• Markus Enzelberger, Interim Chief Scientific Officer
• Anke Linnartz, Vice President and Head of Corporate Communications and Investor Relations
• Malte Peters, Chief Development Officer , Member of the Management Board
• Marc Cluzel M.D., Ph.D., Member of the Supervisory Board
• Karin Eastham CPA, Member of the Supervisory Board
• Wendy Johnson, Member of the Supervisory Board
• Klaus Kuehn, Member of the Supervisory Board

MarketBeat Community Rating for MorphoSys AG (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.